Allogene publishes data from ALPHA, ALPHA2 trials of cemacabtagene ansegedleucel
Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...